This phase 3 clinical trial, known as TenCRAOS, investigated whether the drug tenecteplase could improve vision for patients suffering from acute central retinal artery occlusion. Researchers compared the efficacy and safety of a single intravenous injection of the thrombolytic agent against a standard dose of oral aspirin when administered within a tight 4.5-hour window. The study found that tenecteplase did not provide superior vision recovery compared to aspirin, with approximately one-fifth of patients in both groups achieving the primary visual milestone. Furthermore, the experimental treatment was linked to higher rates of serious adverse events, including a fatal brain hemorrhage. These results suggest that the risks of systemic thrombolysis may outweigh the benefits for this specific eye emergency. Consequently, the authors conclude that tenecteplase should not be routinely used for this condition based on current evidence.